Foghorn Therapeutics (FHTX) News Today $5.01 -0.40 (-7.39%) Closing price 08/28/2025 04:00 PM EasternExtended Trading$5.01 0.00 (0.00%) As of 08/28/2025 06:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock FHTX Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Foghorn Therapeutics to Participate in Key Upcoming Healthcare Conferences in September 2025August 27 at 7:51 AM | quiverquant.comQFoghorn Therapeutics to Participate in Three Upcoming Investor ConferencesAugust 27 at 7:00 AM | globenewswire.comEquities Analysts Issue Forecasts for FHTX Q3 EarningsAugust 9, 2025 | marketbeat.comQ3 EPS Forecast for Foghorn Therapeutics Boosted by AnalystAugust 8, 2025 | marketbeat.comEquities Analysts Set Expectations for FHTX Q1 EarningsAugust 7, 2025 | marketbeat.comFoghorn Therapeutics (FHTX) Expected to Announce Earnings on ThursdayAugust 7, 2025 | marketbeat.comFoghorn Therapeutics (NASDAQ:FHTX) Announces Quarterly Earnings ResultsAugust 6, 2025 | marketbeat.comIs Foghorn Therapeutics (NASDAQ:FHTX) In A Good Position To Invest In Growth?August 5, 2025 | finance.yahoo.comFoghorn Therapeutics Provides Second Quarter 2025 Financial and Corporate UpdateAugust 5, 2025 | globenewswire.comFoghorn Therapeutics Inc. (NASDAQ:FHTX) Receives Consensus Recommendation of "Buy" from AnalystsJuly 24, 2025 | marketbeat.comFoghorn Therapeutics (NASDAQ:FHTX) Stock Price Down 0.5% - What's Next?July 22, 2025 | marketbeat.comFoghorn Therapeutics Inc (FHTX) - Investing.comJuly 3, 2025 | investing.comFoghorn Therapeutics Inc. (NASDAQ:FHTX) Given Consensus Recommendation of "Buy" by BrokeragesJune 29, 2025 | marketbeat.comFoghorn Therapeutics Inc. (NASDAQ:FHTX) Position Boosted by Point72 Asset Management L.P.May 23, 2025 | marketbeat.comFoghorn Therapeutics to Participate in Four Upcoming Investor ConferencesMay 22, 2025 | globenewswire.comQ2 EPS Estimate for Foghorn Therapeutics Cut by AnalystMay 20, 2025 | marketbeat.comWedbush Expects Weaker Earnings for Foghorn TherapeuticsMay 20, 2025 | marketbeat.comJacobs Levy Equity Management Inc. Raises Holdings in Foghorn Therapeutics Inc. (NASDAQ:FHTX)May 19, 2025 | marketbeat.comFoghorn Therapeutics Provides First Quarter 2025 Financial and Corporate UpdateMay 14, 2025 | globenewswire.comDAFNA Capital Management LLC Boosts Stake in Foghorn Therapeutics Inc. (NASDAQ:FHTX)May 10, 2025 | marketbeat.comDeerfield Management Company L.P. Series C Raises Position in Foghorn Therapeutics Inc. (NASDAQ:FHTX)May 10, 2025 | marketbeat.comFoghorn Therapeutics’ SWOT analysis: chromatin pioneer’s stock faces clinical hurdlesMay 7, 2025 | investing.comFoghorn Therapeutics to Participate in the Citizens Life Sciences ConferenceMay 5, 2025 | globenewswire.comFoghorn Therapeutics expands board with biotech veteransMay 2, 2025 | investing.comFoghorn Therapeutics (NASDAQ:FHTX) Receives "Market Outperform" Rating from JMP SecuritiesMay 2, 2025 | marketbeat.comFoghorn Therapeutics (NASDAQ:FHTX) Receives Buy Rating from HC WainwrightMay 2, 2025 | marketbeat.comFoghorn Therapeutics Appoints Neil Gallagher and Stuart Duty to its Board of DirectorsMay 1, 2025 | globenewswire.comFoghorn Therapeutics (FHTX) Projected to Post Quarterly Earnings on MondayApril 30, 2025 | marketbeat.comFoghorn Therapeutics Presents New Preclinical Data on Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Programs and Provides Pipeline UpdateApril 28, 2025 | globenewswire.comFoghorn Therapeutics (NASDAQ:FHTX) Now Covered by Analysts at JMP SecuritiesApril 25, 2025 | marketbeat.comJMP Securities Initiates Coverage of Foghorn Therapeutics (FHTX) with Market Outperform RecommendationApril 23, 2025 | msn.comFoghorn Therapeutics Inc. (NASDAQ:FHTX) Receives Average Recommendation of "Buy" from AnalystsApril 16, 2025 | marketbeat.comFoghorn Therapeutics (NASDAQ:FHTX) Trading 4.1% Higher - Time to Buy?April 16, 2025 | marketbeat.comFoghorn Therapeutics to Host Virtual Investor Event to Review Pipeline Updates in Conjunction with 2025 AACR Annual MeetingApril 15, 2025 | globenewswire.comFoghorn: SMARCA4 Targeting Brings About Treating Up To 10% Of NSCLC PatientsMarch 26, 2025 | seekingalpha.comFoghorn Therapeutics Announces New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and EP300 Degrader Programs at 2025 AACR MeetingMarch 25, 2025 | globenewswire.comFoghorn Therapeutics Inc. (NASDAQ:FHTX) Receives Average Rating of "Buy" from BrokeragesMarch 22, 2025 | marketbeat.com2,029,383 Shares in Foghorn Therapeutics Inc. (NASDAQ:FHTX) Bought by Raymond James Financial Inc.March 22, 2025 | marketbeat.comWhat is B. Riley's Forecast for FHTX Q1 Earnings?March 17, 2025 | marketbeat.comFoghorn Therapeutics' (FHTX) "Buy" Rating Reaffirmed at HC WainwrightMarch 8, 2025 | marketbeat.comFoghorn Therapeutics (NASDAQ:FHTX) Posts Quarterly Earnings Results, Beats Expectations By $0.13 EPSMarch 7, 2025 | marketbeat.comFoghorn Therapeutics Provides Financial Update for 2024 and 2025 Strategic OutlookMarch 6, 2025 | globenewswire.comInstitutional investors may adopt severe steps after Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) latest 14% drop adds to a year lossesFebruary 28, 2025 | finance.yahoo.comFoghorn Therapeutics (FHTX) Projected to Post Quarterly Earnings on ThursdayFebruary 27, 2025 | marketbeat.comFoghorn Therapeutics to Participate in Two Upcoming Investor ConferencesFebruary 25, 2025 | globenewswire.comFoghorn Therapeutics Inc. (NASDAQ:FHTX) Receives Consensus Recommendation of "Buy" from BrokeragesFebruary 24, 2025 | marketbeat.comFoghorn Therapeutics Inc. (NASDAQ:FHTX) Sees Large Increase in Short InterestFebruary 17, 2025 | marketbeat.comWhat is B. Riley's Estimate for FHTX FY2024 Earnings?February 3, 2025 | marketbeat.comB. Riley Upgrades Foghorn Therapeutics (NASDAQ:FHTX) to "Strong-Buy"January 31, 2025 | marketbeat.comB. Riley Securities Initiates Coverage of Foghorn Therapeutics (FHTX) with Buy RecommendationJanuary 30, 2025 | msn.com Get Foghorn Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FHTX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. FHTX Media Mentions By Week FHTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. FHTX News Sentiment▼1.221.03▲Average Medical News Sentiment FHTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. FHTX Articles This Week▼31▲FHTX Articles Average Week Get the Latest News and Ratings for FHTX and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Foghorn Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Xeris Biopharma News Today Precigen News Today Enliven Therapeutics News Today Collegium Pharmaceutical News Today CureVac News Today Pharvaris News Today Calliditas Therapeutics AB (publ) News Today LENZ Therapeutics News Today Structure Therapeutics News Today Intellia Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:FHTX) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Foghorn Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Foghorn Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access